DNASeq
Exome/DNA analysis using next generation sequencing (DNASeq)
Part 1 Sample Preparation and Exon Sequencing
- Introduction to 100,000 Genome Project and exome/DNA analysis
- DNA sample preparation
- Overview of next generation sequencing platforms
- Overview of Exone Capture kits (Agilent SureSelect, Illumina TruSeq and Nimblegen SeCan EZ)
- Overview of file formats (FASTQ, SAM/BAM, BED, GTF and VCF files)
- Introduction to the Galaxy Bioinformatics platform
- Quality control of raw sequencing data (FASTQC)
- Mapping of sequencing data to a reference genome (BWA)
- Quality control of aligned data (PICARD)
- Viewing data using genome browsers (IGV)
- Tools for calling SNV and Indels
- Variant annotation (location, effect, novelty etc)
- Analysis of affected genes (pathways, gene ontology and disease association)
Cost: £249
For reservations contact mailto:m.a.lindsay@bath.ac.uk
Course Feedback (Overall 4.3/5.0 from > 200 delegates)
'Very instructive, friendly speakers'
'Excellent. Everything very clearly presented'
'Excellent content and teaching'
'Very clear and covers a lot'
Course Trainers
Professor Mark A Lindsay
Mark Lindsay is Professor of Molecular and Computational Pharmacology at the University of Bath He obtained a BA in Natural Sciences from Cambridge University and a PhD investigating the mechanism of insulin release from Nottingham in 1991. Following an initial post-doctoral position in renal disease, he moved to the National Heart and Lung Institute, Imperial College London in 1994 where he investigated the mechanisms regulating the inflammatory response in the airways and lung. Between 2001 and 2005 he worked at AstraZeneca Pharmaceuticals, where he headed a project team examining the utility of siRNAs and antisense for target discovery and as novel therapeutics. Since returning to academia in 2005, he has worked at Imperial College London and the Universities of Manchester and Bath. Work within his group has focused upon examining the role of the transcriptome in the inflammation associated with multiple diseases. Professor Lindsay has recently undertaken a 12 month secondment as the acting Head of Biology at the MRC Nucleic Acid Therapy Accelerator at the Harwell Science Campus (near Oxford). The nucleic acid therapy accelerator (NATA) is a new UK research initiative with a mission to accelerate the development of nucleic acid therapeutics, building partnerships with industry and academia from around the world.